CL2017002767A1 - Nuevas proteínas específicas para cd137. - Google Patents

Nuevas proteínas específicas para cd137.

Info

Publication number
CL2017002767A1
CL2017002767A1 CL2017002767A CL2017002767A CL2017002767A1 CL 2017002767 A1 CL2017002767 A1 CL 2017002767A1 CL 2017002767 A CL2017002767 A CL 2017002767A CL 2017002767 A CL2017002767 A CL 2017002767A CL 2017002767 A1 CL2017002767 A1 CL 2017002767A1
Authority
CL
Chile
Prior art keywords
lipocalin muteins
bind
compositions
nucleic acid
acid molecules
Prior art date
Application number
CL2017002767A
Other languages
English (en)
Inventor
Marlon Hinner
Christine Rothe
Shane Olwill
Andrea Allersdorfer
Aiba Rachida Siham Bel
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Publication of CL2017002767A1 publication Critical patent/CL2017002767A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Abstract

<p>La presente descripción provee muteínas de lipocalina humana que se unen a CD137 y pueden ser utilizadas en aplicaciones farmacéuticas, por ejemplo, como agentes anti-cáncer y/o moduladores inmunológicos para el tratamiento o la prevención de enfermedades humanas tales como cáncer, enfermedades infecciosas y enfermedades autoinmunes. La presente descripción también se refiere a métodos para preparar muteínas de lipocalina que se unen a CD137 descriptas en la presente, así como también a composiciones que comprenden dichas muteínas de lipocalina. La presente descripción además se refiere a moléculas de ácido nucleico que codifican dichas muteínas de lipocalina y a métodos para la generación de dichas muteínas de lipocalina y moléculas de ácido nucleico. Además, la solicitud divulga usos terapéuticos y/o de diagnóstico de estas muteínas de lipocalina, así como también composiciones que comprenden una no más de dichas muteínas de lipocalina.</p>
CL2017002767A 2015-05-04 2017-11-02 Nuevas proteínas específicas para cd137. CL2017002767A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15166184 2015-05-04

Publications (1)

Publication Number Publication Date
CL2017002767A1 true CL2017002767A1 (es) 2018-07-20

Family

ID=53054879

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002767A CL2017002767A1 (es) 2015-05-04 2017-11-02 Nuevas proteínas específicas para cd137.

Country Status (20)

Country Link
US (2) US11261221B2 (es)
EP (2) EP3292137B1 (es)
JP (2) JP6884708B2 (es)
KR (1) KR20170142200A (es)
CN (2) CN114573680A (es)
AU (1) AU2016258952C1 (es)
BR (1) BR112017020426A2 (es)
CA (1) CA2980839A1 (es)
CL (1) CL2017002767A1 (es)
DK (1) DK3292137T3 (es)
ES (1) ES2932425T3 (es)
HK (1) HK1249527A1 (es)
IL (1) IL254516B (es)
MX (1) MX2017014082A (es)
NZ (1) NZ736560A (es)
PH (1) PH12017501583A1 (es)
RU (1) RU2736312C2 (es)
SG (1) SG11201708339QA (es)
WO (1) WO2016177762A1 (es)
ZA (1) ZA201705960B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2707126C2 (ru) 2009-12-07 2019-11-22 Пирис Аг МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
US10774119B2 (en) 2014-05-22 2020-09-15 Pieris Pharmaceuticals Gmbh Specific-binding polypeptides and uses thereof
BR112017015773A2 (pt) 2015-01-28 2018-03-27 Pieris Pharmaceuticals Gmbh muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
RU2736312C2 (ru) 2015-05-04 2020-11-13 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Белки, специфичные в отношении cd137
SG11201708334RA (en) 2015-05-04 2017-11-29 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
ES2938525T3 (es) 2015-05-18 2023-04-12 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anticanceroso
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
AU2016363668A1 (en) 2015-11-30 2018-05-24 Pieris Australia Pty Ltd. Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
US20210113528A1 (en) 2018-03-26 2021-04-22 4Sc Ag Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy
CA3100119A1 (en) * 2018-07-31 2020-02-06 Pieris Pharmaceuticals Gmbh Fusion protein specific for cd137 and pd-l1
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
WO2020201038A1 (en) 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
WO2020208049A1 (en) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
CA3154881A1 (en) 2019-11-04 2021-05-14 Shane Olwill Her2/4-1bb bispecific fusion proteins for the treatment of cancer
WO2021245240A1 (en) 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb
US20230366884A1 (en) 2020-09-18 2023-11-16 Pieris Pharmaceuticals Gmbh Biomarker methods and uses
WO2022200412A2 (en) 2021-03-23 2022-09-29 Pieris Pharmaceuticals Gmbh Her2/4-1bb bispecific fusion proteins for the treatment of cancer
WO2022200478A1 (en) 2021-03-24 2022-09-29 Pieris Pharmaceuticals Gmbh Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
WO2023118497A1 (en) 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
WO2024064713A1 (en) 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
CN1073119C (zh) 1994-05-18 2001-10-17 吸入治疗系统公司 干扰素干粉配方的方法及组合物
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (fr) 1996-10-14 1998-04-23 Firm Forsat Ltd. Procede de preparation de dispersions a base de composants chromogenes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
EP1087778B1 (en) 1998-06-08 2005-10-26 F. Hoffmann-La Roche Ag Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
KR101516023B1 (ko) 2006-08-01 2015-04-30 피어이스 에이지 눈물 리포칼린 돌연변이 단백질 및 이를 얻는 방법
CN101516907B (zh) * 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
CA2702612C (en) 2007-10-19 2016-05-03 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
EP3381933B1 (en) * 2008-06-24 2020-06-03 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
RU2707126C2 (ru) * 2009-12-07 2019-11-22 Пирис Аг МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ
CN103154023B (zh) 2010-08-16 2017-04-05 皮里斯制药有限公司 铁调素的结合蛋白
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
EP2968490A1 (en) 2013-03-14 2016-01-20 Daiichi Sankyo Co., Ltd. Novel binding proteins for pcsk9
CA2891557A1 (en) * 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
EP3094650A2 (en) * 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
BR112017015773A2 (pt) 2015-01-28 2018-03-27 Pieris Pharmaceuticals Gmbh muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
TN2017000348A1 (en) 2015-02-18 2019-01-16 Sanofi Sa Novel proteins specific for pyoverdine and pyochelin
SG11201708334RA (en) * 2015-05-04 2017-11-29 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
RU2736312C2 (ru) 2015-05-04 2020-11-13 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Белки, специфичные в отношении cd137
ES2938525T3 (es) * 2015-05-18 2023-04-12 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anticanceroso
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137

Also Published As

Publication number Publication date
CA2980839A1 (en) 2016-11-10
JP6884708B2 (ja) 2021-06-09
CN107820500A (zh) 2018-03-20
IL254516A0 (en) 2017-11-30
AU2016258952C1 (en) 2020-12-24
CN114573680A (zh) 2022-06-03
RU2017135599A3 (es) 2019-09-27
CN107820500B (zh) 2022-03-01
IL254516B (en) 2021-10-31
NZ736560A (en) 2021-12-24
EP4177262A1 (en) 2023-05-10
JP7149363B2 (ja) 2022-10-06
JP2021097695A (ja) 2021-07-01
US11261221B2 (en) 2022-03-01
KR20170142200A (ko) 2017-12-27
JP2018515084A (ja) 2018-06-14
PH12017501583A1 (en) 2018-02-05
EP3292137A1 (en) 2018-03-14
WO2016177762A1 (en) 2016-11-10
SG11201708339QA (en) 2017-11-29
US20180148484A1 (en) 2018-05-31
BR112017020426A2 (pt) 2018-06-26
JP2022177231A (ja) 2022-11-30
MX2017014082A (es) 2018-06-28
RU2736312C2 (ru) 2020-11-13
AU2016258952B2 (en) 2020-08-27
AU2016258952A1 (en) 2017-11-09
HK1249527A1 (zh) 2018-11-02
DK3292137T3 (da) 2022-10-17
RU2017135599A (ru) 2019-06-04
EP3292137B1 (en) 2022-09-07
ZA201705960B (en) 2023-03-29
US20220144901A1 (en) 2022-05-12
ES2932425T3 (es) 2023-01-19

Similar Documents

Publication Publication Date Title
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CL2017001364A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
MX2017014083A (es) Polipeptido de fusion anti-cancer.
MX2018001567A (es) Novedosos polipeptidos de fusion especificos para lag-3 y pd-1.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
MX2017014716A (es) Polipeptido de fusion anti-cancer.
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
EA201591925A1 (ru) Терапевтические композиции и их применение
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2019008434A (es) Muteínas de lipocalina con afinidad de unión por lag-3.
GT201800102A (es) Polipéptidos que inhiben cd4ol
AR112069A1 (es) Inmunoglobulinas que fijan aggrecan